- Home
- FTS vs DGX Comparison
FTS vs DGX Comparison
Compare FTS & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTS | DGX |
|---|---|---|
| Founded | 1885 | 1967 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.5B | 26.2B |
| IPO Year | 2016 | 1996 |
Fundamental Metrics
Financial Performance| Metric | FTS | DGX |
|---|---|---|
| Price | $53.18 | $237.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 13 |
| Target Price | $67.00 | ★ $214.38 |
| AVG Volume (30 Days) | 615.3K | ★ 892.5K |
| Earning Date | 05-06-2026 | 04-21-2026 |
| Dividend Yield | ★ 3.22% | 1.82% |
| EPS Growth | N/A | ★ 13.78 |
| EPS | N/A | ★ 5.08 |
| Revenue | N/A | ★ $11,035,000,000.00 |
| Revenue This Year | $11.05 | $7.53 |
| Revenue Next Year | $5.32 | $3.77 |
| P/E Ratio | ★ $22.72 | $46.49 |
| Revenue Growth | N/A | ★ 11.78 |
| 52 Week Low | $49.60 | $171.18 |
| 52 Week High | $59.40 | $248.84 |
Technical Indicators
Market Signals| Indicator | FTS | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 33.96 | 48.15 |
| Support Level | $50.60 | $230.43 |
| Resistance Level | $58.05 | $240.13 |
| Average True Range (ATR) | 0.65 | 5.39 |
| MACD | -0.06 | -1.07 |
| Stochastic Oscillator | 14.98 | 44.49 |
Price Performance
Historical ComparisonAbout FTS Fortis Inc.
Fortis owns and operates eight utility transmission and distribution subsidiaries in Canada and the United States, serving 3.5 million electricity and gas customers. The company has smaller stakes in electricity generation and several Caribbean utilities. Subsidiary ITC operates electric transmission in seven US states, with more than 16,000 miles of high-voltage transmission lines in operation.
About DGX Quest Diagnostics Incorporated
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.